InVentiv bets on PR with Chandler Chicco pickup

Share this article:
Snowballing InVentiv Health signaled interest in the PR sector with its pickup of a big independent PR shop.

The firm last month announced two acquisitions—those of indie healthcare PR shop Chandler Chicco Agency and AWAC, which offers cost containment services to medical payors.

The healthcare marketing and communications company's acquisition of the PR firm, which boasts gross income of $50 million and a staff of 250 spread throughout offices in New York, Los Angeles, Washington, London and Paris, follows its pickup of Chamberlain PR in February.
The addition gives the company a broad-based shop with a substantial corporate practice and international reach to compliment Chamberlain's high-science product PR focus. InVentiv Communications president and CEO R. Blane Walter called Chandler Chicco a good fit in a sector primed for expansion.

“They're kind of the InChord of the PR space,” he said, referring to InVentiv's advertising predecessor company. “The PR environment is growing as people look for more creative ways to reach consumers in a cost-efficient manner.”

Chandler Chicco also deepens InVentiv's relationships with key clients including Allergan, Sanofi-Aventis, Bristol-Myers Squibb and Novartis. Robert Chandler and Gianfranco Chicco will continue to lead the business, reporting to InVentiv Communications president and COO William O'Donnell.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...